



**MEDTECS INTERNATIONAL CORPORATION LIMITED**  
(Incorporated in Bermuda)

## **MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)**

---

### **1. INTRODUCTION**

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025, 25 April 2025, 8 May 2025, and 28 May 2025 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

### **2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)**

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that the Liquidator had on 11 June 2025 issued a notice of meeting to the creditors of Resilient Medical to convene a meeting in accordance with Section 148 of the IRDA ("**Meeting**"), for the purpose of laying an account of the conduct of the winding up and the disposal of Resilient Medical's property, and providing explanation of the account, as a necessary step to finalise Resilient Medical's winding up given that there are no remaining matters to be dealt with in the liquidation. The Meeting will be held via videoconference on 11 July 2025 at 3:30 p.m.. While the Meeting is primarily for explanatory purposes, creditors or contributories may raise queries at the Meeting, which the Liquidator may address as appropriate.

Following the Meeting, the Liquidator will complete the necessary post-Meeting filings, notify stakeholders of the intended Court application, and prepare and submit the relevant documents to the Official Receiver and the Court. The liquidation will conclude upon the Court's approval and issuance of the dissolution order for Resilient Medical and for the Liquidator's release as liquidator of Resilient Medical.

### **3. FINANCIAL IMPACT**

As disclosed in Note 16(iv) of the audited financial statements of the Company for the financial year ended 31 December 2024 set out in the Company's annual report dated 15 April 2025, management had assessed and concluded that the Group lost control of Resilient Medical from 27 December 2024, being the date of the winding up application. As a result, the Group deconsolidated Resilient Medical and its subsidiaries from its financial statements for the financial year ended 31 December 2024.

As disclosed in the Company's announcement dated 28 May 2025, following the completion of the transfer of the entire issued share capital in RMKH SG to the Company on 28 May 2025 pursuant to the dividend in specie declared by Resilient Medical, RMKH SG is a direct wholly-owned subsidiary of the Company and the Company will consolidate both RMKH SG and its wholly-owned subsidiary, RMKH Cambodia into the Group's financial statements.

As at the date of this announcement, the Company is still assessing the impact of the winding up of Resilient Medical on the net tangible assets per share of the Company and the earnings per share of the Company for the current financial year ending 31 December 2025, pending any further orders (if any) to be made by the Court in the dissolution order for Resilient Medical in due course.

The Company will also release further announcements to update its shareholders as and when there are material developments in relation to the winding up of Resilient Medical in between the monthly updates.

#### 4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

Submitted by Mr Clement Yang, Executive Chairman, on 30 June 2025 to the SGX-ST.

---

*This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").*

*This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.*

*The contact persons for the Sponsor are Ms. Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.*